Partnership with NMX
January 17, 2024

Molecular Forecaster Inc. Partners with NMX Research and Solutions Inc. to Deliver Expanded Hypothesis-Driven Drug Design Services

MONTREAL, QUEBEC, January 17, 2024 – Molecular Forecaster Inc. (MFI) is excited to announce a new partnership with NMX Research and Solutions Inc. (NMX) that will expand the service offerings of both companies.

MFI and NMX are each focused on accelerating the preclinical stages of the drug discovery process. MFI is a Research-as-a-Service (RaaS) organization specializing in computer-aided drug design. MFI’s user-focused software platforms integrate suites of tools to facilitate custom experimental design and enable complete workflow automation, without the need for third-party applications. NMX is a leader in employing its biophysics platform (especially nuclear magnetic resonance (NMR) spectroscopy) to help identify drug leads for challenging disease targets.

“Both MFI and NMX have niche domain knowledge that can be a game-changer for organizations at the earliest stages of the drug discovery process, where every penny and second counts,” says Josh Pottel, MFI’s CEO. “By partnering on projects, we create opportunities for the entire discovery process to become more iterative, and we are able to deliver a more integrated and effective design-make-test-analyze cycle for our clients without sacrificing our domain expertise.”

The partnership facilitates opportunities to accelerate the confirmation of specific hypotheses or to inform structure-activity relationships. It also enables the two companies to work together to identify, benchmark, and screen fragment molecules prior to testing. For example, structural data determined by NMX can inform MFI in the development of robust and realistic protein models, which MFI can then use to virtually screen libraries of compounds to identify those for testing. NMX can then verify whether the compounds proposed are able to bind in the expected site, and then serve as seeds for designing novel leads.

“Fragment-based lead discovery is one of the most promising strategies for discovering new medicines, but it’s hard,” says Lucie Laurin, NMX’s Managing Director. “Part of what we do at NMX is find ways to remove the barriers to its practical application, evaluating and reengineering the steps along the FBLD pathway. This partnership with MFI gives us actionable insights for project next steps as we work to find the seeds for our customers’ leads.”

Chemical research is complex, dynamic, and challenging. Taking a highly collaborative approach to computer-aided drug design in combination with fragment-based lead discovery and other biophysical methods can accelerate the process. Contact us to learn more about how MFI and NMX can support your gene-to-lead research.


About Molecular Forecaster Inc.

Molecular Forecaster Inc. is a Research as a Service (RaaS) company, providing computer-aided drug discovery (CADD) technology and expertise to biotechs and pharmas around the world. With proprietary software tools, and expertise in drug discovery, quantum mechanics, molecular dynamics, chemoinformatics and artificial intelligence, our team of chemists, biologists and computer scientists are helping organizations large and small fast-track their preclinical drug design and discovery programs.


About NMX

NMX Research and Solutions, Inc. discovers drug leads for challenging disease targets, employing its deep biophysics expertise and innovation to help clients and partners launch and accelerate their drug discovery programs.